Patent vs. Regulatory Exclusivity: The Drug Industry’s Two-Layer Protection System Explained
What You Actually Need to Know About the Dual Shield Most people conflate drug patents with drug exclusivity. They are […]
First to File. First to Profit: The Complete Guide to Paragraph IV Certifications and 180-Day Exclusivity
How generic drug companies legally exploit the Hatch-Waxman framework to generate billion-dollar windfalls — and how brand manufacturers fight back
20 Years on Paper: The Real Guide to Drug Patent Duration in the United States
The Patent Clock Nobody Shows You The standard answer to “how long does a patent last?” is 20 years. You
20 Years on Paper: The Real Guide to Drug Patent Duration in the United States Read Post »
When to Switch: Using Loss-of-Exclusivity Data to Time Generic and Biosimilar Formulary Substitutions
How payers, PBMs, and formulary committees can convert LOE intelligence into measurable cost savings — and why most of them
Read Their Drug Pipeline Before They Publish It: Competitive Forecasting with Pharmaceutical Patent Intelligence
A Practical Guide to Tracking Competitors’ R&D Pipelines Before They Make Headlines The Intelligence Gap That Costs Billions Every pharmaceutical
Pick the Right Patent Or Leave Billions on the Table: The Definitive Guide to the One-Patent-Per-Product Rule and PTE Selection Strategy
The Decision That Defines Decades of Revenue Somewhere between the FDA approval notice hitting a pharmaceutical company’s inbox and the
South American Drug Patents: The Definitive Country-by-Country Breakdown
Patent Terms, Data Exclusivity, Compulsory Licensing, and Generic Entry Across 11 Markets Why South America Is the World’s Most Contested
South American Drug Patents: The Definitive Country-by-Country Breakdown Read Post »
Win More 505(b)(2) Business: A guide for CDMOs and specialty labs targeting companies developing 505(b)(2) follow-on drugs
A $28 Billion Opportunity Most Vendors Are Missing The 505(b)(2) pathway generates billions in annual drug revenue and runs on
Build the Wall: How Pharma Companies Layer NCE and Orphan Drug Exclusivity to Lock Out Generics
Pharmaceutical executives routinely talk about patent cliffs as if they were acts of nature. They are not. The shape of
